First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507486-26-00

Acronym

22049

Enrollment

Registered

2024-01-30

Start date

2024-08-20

Completion date

Unknown

Last updated

2025-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expression

None listed

Sex/Gender

Male

Age

18 Years to No maximum

Belgium, Finland, Italy, Netherlands, Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026